Galmed Pharmaceuticals Ltd
GLMD1.630USD
+0.080+5.16%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
3.68MCap. mercado
PérdidaP/E TTM
Más Datos de Galmed Pharmaceuticals Ltd Compañía
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Información de la empresa
Símbolo de cotizaciónGLMD
Nombre de la empresaGalmed Pharmaceuticals Ltd
Fecha de salida a bolsaMar 13, 2014
Director ejecutivoMr. Allen Baharaff
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 13
Dirección16 Tiomkin Street
CiudadTEL AVIV-YAFO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal6578317
Teléfono97236938448
Sitio Webhttps://www.galmedpharma.com
Símbolo de cotizaciónGLMD
Fecha de salida a bolsaMar 13, 2014
Director ejecutivoMr. Allen Baharaff
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baharaff (Allen)
0.68%
Schonfeld Strategic Advisors LLC
0.46%
Virtu Americas LLC
0.20%
Two Sigma Investments, LP
0.20%
Cambridge Investment Research Advisors, Inc.
0.19%
Other
98.27%
Accionistas
Accionistas
Proporción
Baharaff (Allen)
0.68%
Schonfeld Strategic Advisors LLC
0.46%
Virtu Americas LLC
0.20%
Two Sigma Investments, LP
0.20%
Cambridge Investment Research Advisors, Inc.
0.19%
Other
98.27%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
1.20%
Hedge Fund
0.66%
Research Firm
0.20%
Investment Advisor
0.19%
Other
97.75%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
36
133.14K
2.44%
+18.75K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
2023Q2
57
33.03K
13.93%
-6.52K
2023Q1
63
32.53K
145.11%
-12.28K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baharaff (Allen)
36.94K
1.64%
+8.83K
+31.44%
Mar 21, 2025
Schonfeld Strategic Advisors LLC
25.19K
1.12%
-206.00
-0.81%
Mar 31, 2025
Virtu Americas LLC
11.13K
0.49%
+11.13K
--
Mar 31, 2025
Two Sigma Investments, LP
11.02K
0.49%
+11.02K
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
7.38K
0.33%
+7.29K
+7435.71%
Mar 31, 2025
Nehemya (Guy)
6.28K
0.28%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.28%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.28%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.15%
+3.12K
+1148.16%
Mar 21, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
Fecha
Tipo
Relación
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
